Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2526
DELISTED
Enterprise Bancorp
EBTC
| $1.02M | ﹤0.01% |
42,700
-13,500
| -24% | -$313K |
2015 Q4
18 quarters
|
|
2527
DELISTED
Noble Corporation
NE
| $1.02M | ﹤0.01% |
3,165,522
+1,554,985
| +97% | +$399K |
2019 Q3
3 quarters
|
|
2528
Fuel Tech
FTEK
$51.5M
| $1.01M | ﹤0.01% |
1,206,638
+15,100
| +1% | +$10.5K |
2015 Q1
21 quarters
|
|
2529
American Vanguard Corp
AVD
$47.2M
| $1.01M | ﹤0.01% |
73,525
-115,364
| -61% | -$1.55M |
2015 Q3
19 quarters
|
|
2530
Cellectar Biosciences
CLRB
$13.7M
| $1.01M | ﹤0.01% |
2,635
+1,861
| +240% | +$781K |
2018 Q3
7 quarters
|
|
2531
MVB Financial
MVBF
$375M
| $1.01M | ﹤0.01% |
76,101
+15,701
| +26% | +$211K |
2019 Q3
3 quarters
|
|
2532
Assured Guaranty
AGO
$3.08B
| $1.01M | ﹤0.01% |
41,410
-169,790
| -80% | -$4.63M |
2017 Q3
11 quarters
|
|
|
WPG
2533
DELISTED
Washington Prime Group Inc.
WPG
| $1.01M | ﹤0.01% |
+133,320
| New | +$979K |
2020 Q2
0 quarters
|
|
2534
Northern Dynasty Minerals
NAK
$630M
| $1M | ﹤0.01% |
+703,604
| New | +$651K |
2020 Q2
0 quarters
|
|
2535
Vanguard Health Care ETF
VHT
$19.3B
| $1M | ﹤0.01% |
+5,200
| New | +$976K |
2020 Q2
0 quarters
|
|
|
OYST
2536
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $1M | ﹤0.01% |
+34,700
| New | +$1.05M |
2020 Q2
0 quarters
|
|
2537
Pro-Dex
PDEX
$202M
| $999K | ﹤0.01% |
56,060
+18,206
| +48% | +$323K |
2017 Q3
11 quarters
|
|
2538
Fortune Brands Innovations
FBIN
$4.66B
| $998K | ﹤0.01% |
18,259
-124,490
| -87% | -$5.79M |
2020 Q1
1 quarter
|
|
2539
Cypherpunk Technologies Inc
CYPH
$317M
| $998K | ﹤0.01% |
47,750
+30,470
| +176% | +$653K |
2020 Q1
1 quarter
|
|
|
NUVA
2540
DELISTED
NuVasive, Inc.
NUVA
| $996K | ﹤0.01% |
17,888
+1,388
| +8% | +$80.3K |
2019 Q2
4 quarters
|
|
2541
Paylocity
PCTY
$8.17B
| $992K | ﹤0.01% |
+6,800
| New | +$791K |
2020 Q2
0 quarters
|
|
|
RBCN
2542
DELISTED
Rubicon Technology, Inc.
RBCN
| $992K | ﹤0.01% |
122,127
+1,523
| +1% | +$11.9K |
2014 Q3
23 quarters
|
|
|
SMTX
2543
DELISTED
SMTC Corporation
SMTX
| $991K | ﹤0.01% |
327,033
-23,400
| -7% | -$68.7K |
2013 Q2
28 quarters
|
|
2544
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $989K | ﹤0.01% |
255
-26
| -9% | -$86.3K |
2018 Q3
7 quarters
|
|
|
AXLA
2545
DELISTED
Axcella Health Inc. Common Stock
AXLA
| $989K | ﹤0.01% |
+7,152
| New | +$875K |
2020 Q2
0 quarters
|
|
2546
Tiziana Life Sciences
TLSA
$151M
| $987K | ﹤0.01% |
+384,096
| New | +$705K |
2020 Q2
0 quarters
|
|
|
NAVB
2547
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
| $981K | ﹤0.01% |
+249,000
| New | +$476K |
2020 Q2
0 quarters
|
|
2548
Peoples Bancorp of North Carolina
PEBK
$233M
| $979K | ﹤0.01% |
55,396
+653
| +1% | +$11.6K |
2017 Q2
12 quarters
|
|
2549
DELISTED
Cadence Bancorporation
CADE
| $979K | ﹤0.01% |
110,547
-260,100
| -70% | -$1.86M |
2019 Q3
3 quarters
|
|
|
MTSC
2550
DELISTED
MTS Systems Corp
MTSC
| $977K | ﹤0.01% |
55,518
-197,700
| -78% | -$3.65M |
2013 Q2
28 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.